SUNNYVALE, CALIFORNIA
(February 17, 2009)
Impac Software, part of the Elekta Group, today announced its
collaboration with the National Comprehensive Cancer Network (NCCN)
to license NCCN’s clinical care content to clinicians utilizing
MOSAIQ®, Impac’s oncology electronic medical record (EMR).
MOSAIQ will be the first oncology EMR to embed an intelligent
search engine that dynamically links to the NCCN Clinical
Practice Guidelines in Oncology™. The NCCN Guidelines are used
by clinicians to shape care recommendations covering 97 percent
of all patients with cancer and are updated on a continual
basis. The NCCN Guidelines, developed through an explicit review
of evidence and recommendations from medical experts, address
cancer detection, prevention and risk reduction, workup and
diagnosis and treatment and supportive care.
In addition, MOSAIQ also will provide active access to the NCCN
Drugs & Biologics Compendium™, which delineates uses of drugs
and biologics in the care of patients with cancer, listing
FDA-approved disease indications as well as off-label
recommendations for use, and to the NCCN Chemotherapy Order
Templates™.
“NCCN is looking forward to working with Impac Software to
provide another important channel for distribution of the NCCN
Guidelines,” says William T. McGivney, PhD, NCCN Chief Executive
Officer. “As a result, clinicians will be provided with ready
access to the best possible treatment options to improve
outcomes for all patients with cancer.”
“Simplified, real-time access to NCCN’s evidence-based clinical
content is expected to enhance the delivery of standardized care
and improve patient safety,” says Joel Goldwein, M.D., Vice
President of Medical Affairs for The Elekta Group. “Many of
Impac’s customers are NCCN Member Institutions; however
simplifying access to NCCN’s clinical content will significantly
increase the use of NCCN Guidelines throughout Impac Software’s
existing customer base, and in hundreds of cancer care centers.”
About MOSAIQ®
Fundamentally integrated to manage the nuances of
both medical and radiation oncology charting, Impac Software’s
comprehensive EMR, MOSAIQ provides a clear, fast and flexible
means of documenting patient information throughout the medical
assessment and chemotherapy administration process. With the
ability to include diagnostic images, lab results, and external
documentation, MOSAIQ provides clinicians with a complete
picture of patient care. For more information, visit
www.impac.com/mosaiq.
About Impac Software
Impac Software is part of the Elekta Group, a human care company
pioneering significant innovations and clinical solutions for
treating cancer and brain disorders. Impac’s open integration to
multiple healthcare data and imaging systems offers
oncology-specific patient charting and practice management, as
well as systems for anatomic pathology, clinical laboratory and
cancer registry.
Today, Elekta solutions are used in more than 5,000 hospitals
globally, and every day more than 100,000 patients receive
diagnosis, treatment or follow-up with the help of a solution
from the Elekta Group. Elekta employs around 2,500 employees
globally. The corporate headquarter is located in Stockholm,
Sweden, and the company is listed on the Nordic Exchange under
the ticker EKTAb. For more information, please visit
www.impac.com.
About the National Comprehensive Cancer
Network
The National Comprehensive Cancer Network (NCCN), a
not-for-profit alliance of 21 of the world’s leading cancer
centers, is dedicated to improving the quality and effectiveness
of care provided to patients with cancer. Through the leadership
and expertise of clinical professionals at NCCN Member
Institutions, NCCN develops resources that present valuable
information to the numerous stakeholders in the health care
delivery system. As the arbiter of high-quality cancer care,
NCCN promotes the importance of continuous quality improvement
and recognizes the significance of creating clinical practice
guidelines appropriate for use by patients, clinicians, and
other health care decision-makers. The primary goal of all NCCN
initiatives is to improve the quality, effectiveness, and
efficiency of oncology practice so patients can live better
lives. For more information, visit
www.nccn.org. |
|
Media Inquiries:
Michelle Lee
PR and Advertising Manager
Tel: +1 770-670-2447
michelle.lee@elekta.com
Global Marketing inquiries:
Peter Ejemyr
Group VP,
Corporate Communications, Tel: +46 733 611 000
peter.ejemyr@elekta.com
Investor inquiries:
Lena Schattauer,
Investor Relations,
Elekta AB
Tel: +46 8 587 257 22, +46 70 595 51 00,
lena.schattauer@elekta.com
Link Disclaimer
|
